

4. RS Research & Simbec Orion





Innovate
UK



SIMBEC-ORION

Turkey's First-ever Phase-1 Clinical Trial of a Targeted Chemotherapy Drug

R&D partnership in Health sector

Co-Founder & COO, Sena Nomak, RS Research
Senior Director Business Development, Qaisar Rafiq, Simbec-Orion

Who we are



Pharmaceutical start-up

Focused in Drug Discovery in Oncology

Established in 2015

SIMBEC-ORION

Full-Service CRO

Expertise in oncology, rare & orphan diseases, respiratory, dermatology and infectious vaccines & diseases.

Merger in 2014



The problem: Cancer

In 2018

9,6

million deaths
WHO, 2018

By 2035

%70

Increase in incidence
WHO, 2017

1 of every

6

deaths
WHO, 2018



Our solution: Targeted Chemotherapy

CHEMOTHERAPY

is effective
but due to toxicity,
dose is limited

TUMOR TARGETING

is well established
but not effective because,
not toxic enough

CLASSICAL CHEMOTHERAPY

TARGETED "SMART" CHEMOTHERAPY


We combine both

TARGETED "SMART" CHEMOTHERAPY



Our solution: Drug Delivery Platforms


1



2



The science





Drug is released via cleavage of an enzyme sensitive linker



Our pipeline

Drug Candidate	Research	Preclinical	IND Approval	Clinical	Platform	Proposed Indication
RS-0139	[Progress bar]			STARTING PHASE-1	I	NSCLC CA Breast CA Prostate CA
RS-0337	[Progress bar]		II		Breast CA	
RS-0461	[Progress bar]			II	Ovarian CA	
RS-0625	[Progress bar]			I	Ovarian CA	
RS-0735	[Progress bar]			I	Pancreas CA	


Leading Candidate RS-0139 Shows Exceptional Effect on Survival



No tumor observed in any RS-0139 mice @ Day 255!



Timeline



Funding received
2 M Euro - ACT VC
Q2 2017

Q1 2015
Company Founded

2010
Research started
Bogazici University

Q2 2018
Switzerland Office
Biopôle

Q1 2020
GMP Production

Phase-I Trial
RS-0139
Q1 2020

Phase-I Trial
RS-0337
Q4 2020

Q1 2021
Phase-II Trial
RS-0139

Looking for strategic partners
to collaborate

Looking for Series-A
investment to fund
Phase-II trials



This is where we merge our powers

- The very first clinical trial of RS Research, which is also the first in many fields in Turkey, will be backed by the experience of Simbec-Orion.
- Sharing a common goal, to improve patients' lives, the result of this cooperation will be a very reliable supporter for RS Research as well as a very good opportunity for Simbec-Orion as a market pioneer.

SIMBEC-ORION

RS
RESEARCH

SimbecOrion's Experience

- Simbec-Orion was created in 2014 by the merger of two very experienced CROs: Simbec Research, a specialist CRO in Early Stage Clinical Development and Orion Clinical, the specialist CRO in Late Stage Clinical Development to create an international, full service, boutique CRO.
- The core expertise is in clinical pharmacology, oncology, rare diseases and areas of unmet medical need.
- The CRO has already delivered studies including > 5,200 patients in the last 5 years alone **with 350 employees** delivering international clinical trials across **4 continents in over 35 countries** from supporting clinical development plans from Phase I-IV.



Thank you!

- Sena Nomak: sn@RSResearch.net
- Qaisar Rafiq: Qaisar.Rafiq@SimbecOrion.com

